Ivan Guerra

Dr. Ivan Guerra

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MCM Chaparro
M Chaparro
AVA Verreth
A Verreth
TLTriana Lobaton
Triana Lobaton
EGE Gravito-Soares
E Gravito-Soares
MJM Julsgaard
M Julsgaard
JGJ P Gisbert
J P Gisbert
The long-term safety of exposure to anti-tumor necrosis factor (anti-TNFα) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNFα drugs in utero with that of children who were not exposed to the drugs. Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNFα medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNFα agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan–Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNFα agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8–1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5–4.3)). In utero exposure to anti-TNFα drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.

22 March 2012 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MCMaría Chaparro
María Chaparro
IGIvan Guerra
Ivan Guerra
PMP. Muñoz‐Linares
P. Muñoz‐Linares
JGJavier P Gisbert
Javier P Gisbert

1 June 2012 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
IGIvan Guerra
Ivan Guerra
AAAlicia Algaba
Alicia Algaba
JPJosé Lázaro Pérez-Calle
José Lázaro Pérez-Calle
MCMaría Chaparro
María Chaparro
IMIgnacio Marín-Jiménez
Ignacio Marín-Jiménez
FBFernando Bermejo
Fernando Bermejo
Anti-tumor necrosis factor (TNF)-alpha agents are widely used for the treatment of both inflammatory bowel disease (IBD) and psoriasis. Psoriatic skin lesions induced by anti-TNF have been described in patients with IBD. We report a case series of psoriasis induced by anti-TNF agents in IBD patients. Systematic analysis of cases of psoriasis induced by anti-TNF in an IBD patient cohort in tertiary hospitals of Madrid. A total of 21 of 1294 patients with IBD treated with anti-TNF-alpha agents developed drug-induced psoriasis (cumulative incidence 1.62%; 95% CI 1.06%-2.47%): 14 patients with infliximab and 7 with adalimumab; seventeen with Crohn's disease, 4 with ulcerative colitis. The onset of skin lesions varied in a wide range of time (after a mean 13±8 doses). The most frequent site of skin lesions was the limbs (62%) followed by the trunk (48%) and the scalp (43%). The psoriasis phenotypes were plaque psoriasis (57%), scalp (14%), palmoplantar pustulosis (14%), pustular generalized psoriasis (5%), guttate (5%) and inverse (5%). Four patients interrupted the anti-TNF treatment, and that led to the complete regression of lesions in 1 of them. The other 17 patients were maintained on anti-TNF therapy and managed with topical steroids. Psoriatic lesions can be induced by anti-TNF drugs. Plaque psoriasis on the extremities and trunk were the most frequent presentations in our series. Topical steroid treatment is effective in most patients. Anti-TNF discontinuance may be reserved for patients with severe psoriasis or patients without response to topical therapy.

1 April 2016 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
IGIvan Guerra
Ivan Guerra
TPTamara Perez-Jeldres
Tamara Perez-Jeldres
MIMarisa Iborra
Marisa Iborra
AAAlicia Algaba
Alicia Algaba
DMDavid Monfort
David Monfort
JGJavier P. Gisbert
Javier P. Gisbert
Background. Psoriasis induced by anti–tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect.Aim. To determine the incidence, c

25 September 2013 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
FBFernando Bermejo
Fernando Bermejo
AAAlicia Algaba
Alicia Algaba
IGIvan Guerra
Ivan Guerra
MCMaría Chaparro
María Chaparro
GDGema De-La-Poza
Gema De-La-Poza
JGJavier P Gisbert
Javier P Gisbert
Objective. Crohn's disease commonly involves the small intestine, which is the site of vitamin B12 and folate absorption. Our aim was to define the prevalence of vitamin B12 and folate deficiency in patients with Crohn's disease and to identify predictive factors associated with such abnormalities. Methods. Two years prospective study of 180 consecutive Crohn's disease patients. Vitamin B12 and folate deficiency was defined as serum levels below 200 pg/ml and 3 ng/ml, respectively. We analysed prevalence of these deficiencies and possible predictive factors including small intestine resection, disease location, activity and duration of disease. Controls were ulcerative colitis patients (n = 70). Results. The prevalence of B12 deficiency in Crohn's disease was 15.6% (95%CI 9.7–20%) compared with 2.8% (95%CI 0.8–9.8%) in ulcerative colitis (p = 0.007). With regard to folate deficiency, the prevalence in patients with Crohn's disease was 22.2% (95%CI 16–28%) compared with 4.3% (95%CI 1.4–12%) in ulcerative colitis (p = 0.001); 7.8% of Crohn's disease patients had macrocytic anemia. Ileal resection was found to be a risk factor for B12 deficiency (OR 2.7; 1.2–6.7; p = 0.02), and disease activity a risk factor for folate deficiency (OR 2.4; 1.2–5.1; p = 0.01). Conclusion. A significant proportion of patients with Crohn's disease suffer from vitamin B12 and/or folate deficiency, suggesting that regular screening should be performed, with closer monitoring in patients with ileal resection or active disease.

1 February 2013 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
JGJavier P Gisbert
Javier P Gisbert
ÁPÁngeles Pérez-Aisa
Ángeles Pérez-Aisa
FBFernando Bermejo
Fernando Bermejo
MCManuel Castro-Fernández
Manuel Castro-Fernández
PAPedro Almela
Pedro Almela
XCXavier Calvet
Xavier Calvet
Second-line bismuth-containing quadruple therapy is complex and frequently induces adverse effects. A triple rescue regimen containing levofloxacin is a potential alternative; however, resistance to quinolones is rapidly increasing. To evaluate the efficacy and tolerability of a second-line triple-regimen-containing levofloxacin in patients whose Helicobacter pylori eradication treatment failed and to assess whether the efficacy of the regimen decreases with time. Prospective multicenter study. In whom treatment with a regimen comprising a proton-pump inhibitor, clarithromycin, and amoxicillin had failed. Levofloxacin (500 mg bid), amoxicillin (1 g bid), and omeprazole (20 mg bid) for 10 days. Eradication was confirmed using the C-urea breath test 4 to 8 weeks after therapy. Compliance/tolerance: Compliance was determined through questioning and recovery of empty medication envelopes. Incidence of adverse effects was evaluated by means of a questionnaire. The study sample comprised 1000 consecutive patients (mean age, 49 ± 15 y, 42% men, 33% peptic ulcer) of whom 97% took all medications correctly. Per-protocol and intention-to-treat eradication rates were 75.1% (95% confidence interval, 72%-78%) and 73.8% (95% confidence interval, 71%-77%). Efficacy (intention-to-treat) was 76% in the year 2006, 68% in 2007, 70% in 2008, 76% in 2009, 74% in 2010, and 81% in 2011. In the multivariate analysis, none of the studied variables (including diagnosis and year of treatment) were associated with success of eradication. Adverse effects were reported in 20% of patients, most commonly nausea (7.9%), metallic taste (3.9%), myalgia (3.1%), and abdominal pain (2.9%). Ten-day levofloxacin-containing therapy is an encouraging second-line strategy, providing a safe and simple alternative to quadruple therapy in patients whose previous standard triple therapy has failed. The efficacy of this regimen remains stable with time.